Relationship between serum trough concentration of Vancomycin and renal injury and clinical efficacy in children with severe infection
ZHU Desheng1 ZENG Fangling2 YAO Zhenya1 ZHOU Wu1
1.The Second Department of Critical Care Medicine, Hu′nan Children′s Hospital, Hu′nan Province, Changsha 410007, China;
2.the Second Department of Emergency Comprehensive, Hu′nan Children′s Hospital, Hu′nan Province, Changsha 410007, China
Abstract：Objective To investigate the relationship between serum trough concentration of Vancomycin and renal injury and clinical efficacy in children with severe infection. Methods A total of 158 children with severe infection admitted to the Hu′nan Children′s Hospital from May 2017 to May 2018 were enrolled. They were divided into group A (n = 52, <5 mg/L), group B (n = 53, 5-10 mg/L) and group C (n = 53, >10 mg/L) according to the serum concentration of Vancomycin. The clinical efficacy, bacteriological efficacy, and renal function related indexes of the three groups were compared. The incidence of adverse reactions during the treatment of the three groups was recorded. Results There was significant difference in the total clinical effective rate among the three groups (P < 0.05). The total clinical effective rate of group B and group C was significantly higher than that of group A, and group B was higher than that of group C, the differences were statistically significant (P < 0.05). The total effective rate of bacteriology in group B and group C was significantly higher than that in group A, and group B was higher than that in group C, the differences were statistically significant (P < 0.05). Urea nitrogen (BUN), serum creatinine (Scr) and cystatin-C (Cys-C) increased after treatment in three groups, and BUN, Scr and Cys-C in group C were higher than those in group A and group B, the differences were statistically significant (P < 0.05), but there was no significant difference in BUN, Scr and Cys-C between two groups after treatment (P > 0.05). There was no significant difference in mortality among the three groups (P > 0.05). Conclusion The different serum concentrations of Vancomycin have different clinical total effective rate and total bacteriological efficiency. Among them, the serum concentration of 5-10 mg/L Vancomycin is better, and the effect on kidney injury is lighter. It will not increase the mortality rate of children and has certain clinical application value.
朱德胜1 曾方玲2 姚震亚1 周武1. 重症感染患儿万古霉素血清谷浓度与肾损伤及临床疗效的关系[J]. 中国医药导报, 2019, 16(24): 119-122,149.
ZHU Desheng1 ZENG Fangling2 YAO Zhenya1 ZHOU Wu1. Relationship between serum trough concentration of Vancomycin and renal injury and clinical efficacy in children with severe infection. 中国医药导报, 2019, 16(24): 119-122,149.
[1] Labibzadeh M，Kaydani GA，Savari M，et al. Emergence of High-level Gentamicin Resistance among Enterococci Clinical Isolates from Burn Patients in South-west of Iran：Vancomycin Still Working [J]. Pol J Microbiol，2018， 67（4）：401-406.
[2] 徐关丽，陈尔真，毛恩强，等.临床药师指引下万古霉素给药方案优化及血药浓度监测研究：附7年数据分析[J].中华危重病急救医学，2018，30（7）：640-645.
[3] Shiohira H，Isagawa S，Yamada S，et al. Applicability of hemodialysis clearance parameter for vancomycin therapeutic drug monitoring during continuous hemodiafiltration in an infant [J]. Pharmazie，2018，73（12）：737-739.
[4] 刘宁，张北源，刘洋，等.肾脏高溶质清除重症感染患者万古霉素合适初始剂量的临床研究[J].中华危重病急救医学，2018，30（7）：646-651.
[5] 何娟，毛恩强，景峰，等.重症急性胰腺炎伴肾功能亢进患者万古霉素的PK/PD研究[J].中华危重病急救医学，2017，29（9）：810-814.
[6] 万古霉素临床应用剂量专家组.万古霉素临床应用剂量中国专家共识[J].中华传染病杂志，2012，30（11）：641-646.
[7] 《抗菌药物临床研究指导原则》写作组.抗菌药物临床研究指导原则[J].中国临床药理学杂志，1987，3（2）：126-130.
[8] Ravinanthanan M，Hegde MN，Shetty VA，et al. Antimicrobial assay of combination surfactant irrigant regimen on vancomycin-resistant Enterococcus faecalis. An in vitro direct contact test [J]. Dent Res J （Isfahan），2018，15（6）：397-403.
[9] 韩清珍，徐杰，张险峰，等.万古霉素依赖性屎肠球菌的生物学特性观察[J].山东医药，2016，56（43）：26-29.
[10] 王牡丹，黄丽娃，陈连国，等.腹透相关性腹膜炎患者血清万古霉素谷浓度与临床疗效的关系[J].中国现代医生，2017，55（12）：9-12.
[11] 徐慧芬，郭红丽.利奈唑胺与万古霉素治疗老年呼吸机相关性肺炎的疗效与安全性研究[J].中国现代医生，2017， 55（33）：89-91.
[12] 赖玮婧，黄艾晶，高芳，等.腹膜透析相关性腹膜炎的致病菌谱和耐药性分析[J].成都医学院学报，2018，13（5）：612-615，620.
[13] Chen QY，Wan J，Yang JH，et al. Vancomycin-induced severe thrombocytopenia in a young infant [J]. Rev Soc Bras Med Trop，2018，51（6）：873-875.
[14] 何娟，毛恩强，景峰，等.SAP患者万古霉素的药代动力学及其影响因素：附7年的数据分析[J].中华危重病急救医学，2017，29（6）：491-495.
[15] 赵文申，林丽萍，崔庆庆，等.ICU患者下呼吸道感染耐甲氧西林金黄色葡萄球菌耐药性分析[J].中国医学装备，2017，14（8）：50-52.
[16] 李瑞云，查干，吴小军.革兰阳性菌血流感染菌种分布及耐药性分析[J].疑难病杂志，2017，16（6）：570-574.
[17] 张慧芳，王瑞兰，舒文，等.成人患者万古霉素血药浓度监测及有效性和安全性评估[J].中华危重病急救医学，2018，30（6）：538-543.
[18] Cotogni P，Barbero C，Rinaldi M. Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery [J]. World J Cardiol，2018，10（11）：234-241.
[19] 张妮，杨保旺，李兴川，等.重症监护病房患儿万古霉素血药浓度的监测[J].临床儿科杂志，2017，35（12）：928-931.
[20] Kim HS，Kim DH，Yoon HJ，et al. Factors Associated with Vancomycin-Resistant Enterococcus Colonization in Patients Transferred to Emergency Departments in Korea [J]. J Korean Med Sci，2018，33（48）：e295.
[21] 陆灏迪，唐莲，薛盛敏，等.万古霉素群体药代动力学在肾功能亢进患者中的临床验证[J].中华危重病急救医学，2018，30（5）：444-448.
[22] 李媛媛，张光莉，田小银，等.革兰阳性球菌重症肺炎患儿万古霉素血药谷浓度影响因素分析[J].临床儿科杂志，2017，35（6）：421-424.
[23] Zahálková K，Chrdle A，Dvo■á■ková O，et al. The Scottish model of vancomycin dosing and therapeutic drug monitoring improves both efficacy and safety of vancomycin therapy [J]. Vnitr Lek，2018，64（7/8）：717-724.
[24] 李尚，智霞，李聪，等.中药灌肠配合连续性肾脏替代疗法治疗重症急性肾损伤临床研究[J].国际中医中药杂志，2018，40（5）：414-417.
[25] 刘小华，李茜，罗璨，等.我院万古霉素临床合理使用评价及血药浓度监测分析[J].中国药房，2017，28（29）：4057-4059.
[26] 罗洁，徐芬，丁岚，等.万古霉素对大鼠肾小管上皮细胞肾损伤定量评价及其机制研究[J].江西医药，2018，53（1）：26-28.
[27] 张烁，熊辉，汪波，等.万古霉素谷浓度水平与临床疗效的关系[J].中华急诊医学杂志，2016，25（6）：757-763.
2019, Vol. 16 
京公网安备 11010502046598号